Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Ulcerative colitis drug market to grow up to $2.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will nearly double from $1.2 billion in 2008 to $2.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

12 Feb 2010

People living with IBD are at high risk of blood clots

People living with Inflammatory Bowel Disease (IBD) are known to be at high risk of blood clots when admitted to hospital during a flare-up of their disease but now new research by scientists at The University of Nottingham has shown that those who are not admitted to hospital during flare-ups are also at risk.

10 Feb 2010

MHI researchers receive $4.8M as grants for genetics and genomic medicine research projects

Two research teams led by Dr. Christine Des Rosiers and Dr. John D. Rioux, both researchers at the Montreal Heart Institute (MHI) and professors at the Universit- de Montr-al, have been awarded grants of $2.5 million and $2.3 million, respectively, to finance research projects on genetics and genomic medicine.

10 Feb 2010

Combination of blueberries and probiotics protects against intestinal disorders

It is already known that blueberries are rich in antioxidants and vitamins. New research from the Lund University Faculty of Engineering in Sweden shows that blueberry fibre are important and can alleviate and protect against intestinal inflammations, such as ulcerative colitis.

9 Feb 2010

Study suggests environmental factors play a significant role in the etiology of Crohn's disease

Although inflammatory bowel disease (IBD) [comprising mainly Crohn's disease (CD) and ulcerative colitis (UC)] is thought to affect about 150 000 people in the United Kingdom, the prevalence of severe IBD is not known. Mortality following hospitalization for IBD is significant but little has been reported on long-term follow-up.

6 Feb 2010

Canadian Institutes of Health Research awards $2.3M for study on integrative biology of inflammatory diseases

A research team led by Dr. John D. Rioux, a researcher at the Montreal Heart Institute (MHI) and professor in the faculty of medicine at the Université de Montréal, has been awarded a grant of more than $2.3 million to finance a major research project on the integrative biology of inflammatory diseases. From among the roughly 70 applications submitted, Dr. Rioux's team is one of six selected by the Canadian Institutes of Health Research to receive the Emerging Team Grant - From Genes to Proteins, Cells, Tissues and Patients.

4 Feb 2010

Loyola surgeon performs complicated laparoscopic procedure

Mild cases of diverticulitis can be treated with changes in diet, rest and antibiotics. However, Bunch's condition was more serious and the chances of recurrences were high. Her doctors at Loyola University Health System said her best option would be surgery to remove the inflamed section of colon.

2 Feb 2010

DNA variations in genes increase risk of developing PI-IBS

Studies of the victims of the Walkerton, Ont. tainted drinking water tragedy have led researchers to discover DNA variations in genes that increase the risk of developing post-infectious irritable bowel syndrome (PI-IBS). The sheer scale of infection and the recording of the health of Walkerton's citizens gave a team of researchers a unique opportunity to study the origin of this disorder.

28 Jan 2010

Data may help identify severity of ulcerative colitis in high-risk patients

Ulcerative colitis (UC) is a chronic disease involving the large intestine which causes inflammation along with local and systemic symptoms. It affects individuals worldwide, with a higher prevalence in Canada. The course of this disease has long been unpredictable, with remission possible in some patients and frequent recurrence in others.

20 Jan 2010

New insights into molecular interaction between probiotics and altered host intestinal ecosystem in IPAA

Total proctocolectomy with ileal J-pouch-anal anastomosis (IPAA) is the surgical treatment of choice for patients with refractory ulcerative colitis (UC). Although the surgery generally cures UC allowing a significant improvement of health-related quality of life, complications can occur after IPAA.

18 Jan 2010

First sulfite-free rectal suspension for UC

sfRowasa™ (mesalamine) Rectal Suspension 4g/60mL –Sulfite-Free Formulation, is the first sulfite-free rectal suspension available for Ulcerative colitis (UC). According to a study published in The American Journal of Gastroenterology, products containing sulfites may exacerbate natural sulfide levels in the colon and may increase inflammation in UC patients. With its sulfite-free preparation, sfRowasa™ offers a new treatment option for the treatment of active, mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.

13 Jan 2010

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN(TM) (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including Crohn's disease.

12 Jan 2010

Significant opportunity for alternative ulcerative colitis biological therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.

5 Jan 2010

Santarus submits rifamycin SV MMX IND to the FDA

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

30 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

Cannabis for Ulcerative Colitis and Crohn's Disease treatment

Chemicals found in cannabis could prove an effective treatment for the inflammatory bowel diseases Ulcerative Colitis and Crohn's Disease, say scientists.

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

FDA approves Santarus’ NDA for immediate-release prescription tablet product

Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for immediate-release omeprazole/sodium bicarbonate/ magnesium hydroxide tablets in 40 mg and 20 mg dosage strengths of omeprazole.

5 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009